Granulocyte-macrophage colony-stimulating factor does not increase the potency or efficacy of a foot-and-mouth disease virus subunit vaccine1

Treatment was begun with a granulocyte colony stimulating factor (G-CSF), methotrexate was kept and the dosage of oral prednisone raised to 40 mg/day, taken for three months,

Objective: The aim of this study was to compare a fractionated dose of 15 ␮g G-CSF/kg of body weight and the conventional dose of granulocyte-colony stimulating factor in respect to

FIGURE 1. Prevailing patterns of foot-and-mouth disease in South America, 1985.. Central America, the Caribbean, and North America, and the risk of its in- troduction into

no caso de indicadores exclusivos ao projeto, é utilizada a percentagem ou a likert scale de modo a avaliar o aumento ou decréscimo da variável em questão. É de notar que existe

In relation to the GM-CSF values on Figure 5, we see the box-plot chart of the GM-CSF pre and post MMC application distribution values and notice that 75% (upper box) of

Among these growth factors, the evaluation of M-CSF and GM-CSF production by macrophages is not just important to understand the immune response, but also to understand

SUMMARY — W e detected the cytokines interleukin-6 (IL-6) and granulocyte macrophage- CSF (GM-CSF) by ELISA in the CSF and serum of 30 HIV-infected patients classified as

4: anticandidal activity of peripheral blood mononuclear cells (PBMC) with or without granulocyte-macrophage colony-stimulating factor (GM- CSF) plus interferon- γ (IFN- γ ),